0001209191-19-034738.txt : 20190605 0001209191-19-034738.hdr.sgml : 20190605 20190605162148 ACCESSION NUMBER: 0001209191-19-034738 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190603 FILED AS OF DATE: 20190605 DATE AS OF CHANGE: 20190605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scranton Richard CENTRAL INDEX KEY: 0001709330 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 19879949 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-03 0 0001396814 Pacira BioSciences, Inc. PCRX 0001709330 Scranton Richard C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Chief Scientific Officer Common Stock 2019-06-03 4 M 0 3010 10.52 A 23111 D Common Stock 2019-06-03 4 M 0 12500 10.81 A 35611 D Common Stock 2019-06-03 4 S 0 15510 43.21 D 20101 D Stock Option (Right to Buy) 10.52 2019-06-03 4 M 0 3010 0.00 D 2022-03-02 Common Stock 3010 0 D Stock Option (Right to Buy) 10.81 2019-06-03 4 M 0 12500 0.00 D 2022-06-05 Common Stock 12500 0 D The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.14 to $43.49, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock options are fully vested. /s/ Kristen Williams, Attorney-in-Fact 2019-06-05